pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” Broad label questioned.

FDA 98

FDA Labelling 98

Pharmaceutical Technology

NOVEMBER 9, 2022

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. An approval decision on the gene therapy, also known as EtranaDez, is expected by the end of this month. million price tag.

FDA 111

FDA 111

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA 40

FDA 40

PharmD Live

JANUARY 25, 2022

A team pharmacist can save time and provide confidence in decision-making because of their expertise and experience. 88% report that their EHR produces clinical benefits for the practice. The variety of circumstances that can be defined as chronic care management supports the prospect of having coordination centered around medication.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

Roots Analysis

SEPTEMBER 13, 2023

These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Labelling 40

Labelling 40

European Pharmaceutical Review

NOVEMBER 10, 2022

The biological characterisation of complex medicines is fundamental to translate these novel therapeutics and associated drug delivery technologies into the clinic; to understand the interplay with biological systems and to evaluate new formulations?. Improved analysis pre-clinically via advanced light microscopy could help.

Labelling 95

Labelling Compounding 95